drugset / Trial / NCT03353298

Lowering Uric Acid in Live Kidney Donors

NCT03353298

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Recently there was described an increase in left ventricular mass after kidney donation. It is uncertain whether this is reversible or not. Allopurinol lowers uric acid in the blood and is normally indicated for gout, but studies have showed that it also can reduce the thickness of the left ventricle of the heart in people with heart- and kidney disease. The investigators wish to give allopurinol or placebo to kidney donors based on randomization and investigate if this has the same effect on kidney donors. The investigators are assessing this by performing a cardiac MRI at baseline and after 9 months of treatment. In addition the investigators wish to see if allopurinol can have beneficial effects on blood pressure and insulin sensitivity as well.

Timeline

Start
2018-01-17
Primary completion
2020-09-25
Completion
2020-09-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 300 mg Oral

Indications

No indication recorded.